Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
as15 (1 trial)
pemigatinib (Pemazyre) (1 trial)
recmage-a3 (1 trial)
Urinary Bladder Neoplasms (Phase 2)
Trials (2 total)
Trial APIs (3 total)